We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 05. 14. | 장 마감 후 (AMC) | $-0.29 | — | — | $0 | — | 예정 |
Rating & price-target changes
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2024. 07. 11. | Maxim Group | — | 투자의견 상향 | Hold → Buy | — | Maxim Group: Hold → Buy |
| 2023. 09. 28. | Maxim Group | — | 투자의견 하향 | Buy → Hold | — | Maxim Group: Buy → Hold |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of Alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Stored first · Google News · Yahoo Finance (English)
BrainStorm (BCLI) CEO granted 1.8M restricted stock units as equity pay - Stock Titan
BrainStorm (BCLI) CEO granted 1.8M restricted stock units as equity pay Stock Titan
BrainStorm Cell (BCLI) EVP Uri Yablonka awarded 150,000 RSUs in new grant - Stock Titan
BrainStorm Cell (BCLI) EVP Uri Yablonka awarded 150,000 RSUs in new grant Stock Titan
Officer at Brainstorm Cell (NASDAQ: BCLI) awarded 100,000 RSUs - Stock Titan
Officer at Brainstorm Cell (NASDAQ: BCLI) awarded 100,000 RSUs Stock Titan
BrainStorm Cell (NASDAQ: BCLI) director receives 200,000 RSUs as stock award - Stock Titan
BrainStorm Cell (NASDAQ: BCLI) director receives 200,000 RSUs as stock award Stock Titan
Brainstorm Cell (BCLI) director receives 120,000-share RSU award - Stock Titan
Brainstorm Cell (BCLI) director receives 120,000-share RSU award Stock Titan
BrainStorm Cell Therapeutics Inc. Appoints Peter J. Pitts to Board of Directors, Effective May 29, 2026 - marketscreener.com
BrainStorm Cell Therapeutics Inc. Appoints Peter J. Pitts to Board of Directors, Effective May 29, 2026 marketscreener.com